ClinicalTrials.gg
CompletedNCT02831673Updated Aug 24, 2023Results posted

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

A Phase 3 interventional study of Dolutegravir (DTG) and Lamivudine (3TC) in Infection, Human Immunodeficiency Virus and HIV Infections, sponsored by ViiV Healthcare. Completed at 90 sites in 18 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-24.

Primary conditionHIV InfectionsRegistry: InfectionsReclassifiedWhy we changed it
Registry
Infections — the first condition term the registry derived for this study.
ClinicalTrials.gg
HIV Infections
Why
  1. The study's listed conditions name HIV Infections, a narrower term within Infections.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by ViiV Healthcare (part of GlaxoSmithKline) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
719
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 132 studies testing lamivudine in HIV Infections — 5 open to participants now, 8 under way, 4 of them phase 3. Lamivudine · HIV Infections.

Enrollment
15th of 126
719 · median 154
Started
2016
with 1 other
Phase 3
50 of 132
2 open now
Registered
111th of 132
by date
Lead sponsor
13 of 132
ViiV Healthcare

Among the 132 studies testing lamivudine in HIV Infections, this one is the 15th largest by enrollment of the 126 interventional ones that give a count, is one of 2 that started in 2016, is one of 50 in phase 3, and was the 111th registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

5 of the 132 studies testing lamivudine in HIV Infections are open now, in 4 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About lamivudine

Lamivudine: first FDA approval 1995 (EPIVIR), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 132 studies testing lamivudine in HIV Infections, or all of them as a file.
02

Study summary

This study will compare safety, efficacy, and tolerability of a two drug regimen of dolutegravir (DTG) plus (+) lamivudine (3TC) administered once daily with DTG plus two nucleoside reverse transcriptase inhibitors (Tenofovir [TDF]/Emtricitabine [FTC] fixed dose combination [FDC]) administered once daily in human immunodeficiency virus (HIV) 1 infected adult participants that have not previously received antiretroviral therapy. The study is designed to demonstrate the non-inferior antiviral activity of DTG plus 3TC regimen to that of DTG plus TDF/FTC FDC and will characterise the long term antiviral activity, tolerability and safety of DTG plus 3TC through Week 148. Approximately, 700 participants will be randomised 1:1 to receive DTG + 3TC or DTG + TDF/FTC FDC. Participants will be stratified by screening HIV 1 ribonucleotide nucleic acid (RNA) levels and by screening CD4+ (cluster of differentiation 4) cell count.

03

Conditions studied

  • Infection, Human Immunodeficiency Virus
  • HIV Infections

Browse trials for

Keywords

  • safety
  • treatment naïve
  • HIV 1
  • dolutegravir plus lamivudine
  • non inferiority
  • tolerability
  • dolutegravir plus tenofovir/emtricitabine
  • efficacy
04

In context

HIV Infections Reclassified

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

This study's enrollment of 719 is above the median of 80 across 3,492 interventional studies indexed under HIV Infections.

Browse HIV Infections studies →

Lead sponsor

ViiV Healthcare is the lead sponsor of 267 studies on the registry; 18 are open to participants now.

Of its 71 completed or terminated interventional studies of FDA-regulated products, 53 (75%) have results posted.

Compared within HIV Infections, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must be an 1 infected adult >=18 years of age (or older, if required by local regulations) at the time of signing the
  • An eligible female participant should not be pregnant (as confirmed by a negative serum human chorionic gonadotrophin (hCG) test at Screening and negative urine test at Baseline), not lactating, and at least one of the following conditions applies

    • Non reproductive premenopausal women are those that have undergone documented tubal ligation or documented hysteroscopic tubal occlusion procedure with follow up confirmation of bilateral tubal occlusion or documented bilateral oophorectomy or hysterectomy
    • Non reproductive premenopausal women are those with 12 months of spontaneous amenorrhea and >=45 years of age
    • Women with agree to follow one of the protocol-defined methods for avoiding pregnancy
  • Should have screening plasma HIV 1 RNA levels of 1000 c/mL to \<=100,000 c/mL. If an independent review of accumulated data from other clinical trials investigating the DTG plus 3TC dual regimen is supportive of the DTG plus 3TC treatment regimen, enrolment will be opened to participants with Screening plasma HIV 1 RNA of 1000 c/mL to \<=500,000 c/mL
  • Participants should be antiretroviral naïve (defined as \<=10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV 1 infection). Participants who received HIV post exposure prophylaxis (PEP) or pre exposure prophylaxis (PrEP) in the past are allowed as long as the last PEP/PrEP dose was >1 year from HIV diagnosis or there is documented HIV seronegativity between the last prophylactic dose and the date of HIV diagnosis
  • Participant or the participants legal representative capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the consent form and the protocol
  • Participants enrolled in France: a participant will be eligible for inclusion in this study only if either affiliated to or a beneficiary of a social security category

Exclusion criteria

Exclusion Criteria

  • Women who are breastfeeding or plan to become pregnant or breastfeed during the study
  • Any evidence of an active centers for disease control and prevention (CDC) Stage 3 disease (CDC, 2014), except cutaneous Kaposi's sarcoma not requiring systemic therapy and historical or current less than 200 cells/mm\^3
  • Participants with severe hepatic impairment (Class C) as determined by classification
  • Unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices, or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones
  • Evidence of virus (HBV) infection or HBV surface antibody (anti-HBs or HBsAb) based on:

Participants positive for HBV surface antigen (HBsAg) at screening will be excluded Participants negative for HBV core antibody (anti HBs) but positive for anti HBc (negative HBsAg status) and positive for HBV deoxyribose nucleic acid (DNA) will be excluded; however, participants positive for anti HBc (negative HBsAg status) and positive for anti HBs (past and/or current evidence) are immune to HBV and will not be excluded

  • Anticipated need for any hepatitis B virus () therapy during the first 48 weeks of the study and for HCV therapy based on interferon or any drugs that have a potential for adverse drug:drug interactions with study treatment throughout the entire study period
  • Untreated syphilis infection positive RPR at Screening without clear documentation of treatment. Participants who are at least 14 days post completed treatment are eligible
  • History or presence of allergy or intolerance to the study drugs or their components or drugs of their class
  • Ongoing other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or resected, non invasive cutaneous squamous cell carcinoma, or cervical, anal or penile intraepithelial neoplasia; other localised malignancies require agreement between the investigator and the Study Medical Monitor for inclusion of the participant
  • Participants who in the Investigator's judgment, poses a significant suicidality risk. Recent history of suicidal behaviour and/or suicidal ideation may be considered as evidence of serious suicide risk
  • Treatment with an 1 immunotherapeutic vaccine within 90 days of Screening
  • Treatment with any of the following agents within 28 days of Screening:

    • Radiation therapy,
    • Cytotoxic chemotherapeutic agents,
    • Any systemic immune suppressant
  • Treatment with any agent, except recognised ART as allowed above, with documented activity against HIV 1 in vitro within 28 days of first dose of study treatment
  • Exposure to an experimental drug or experimental vaccine within either 28 days, 5 half lives of the test agent, or twice the duration of the biological effect of the test agent, whichever is longer, prior to the first dose of study treatment
  • Participants enrolled in France: the participant has participated in any study using an drug during the previous 60 days or 5 half lives, or twice the duration of the biological effect of the experimental drug or vaccine, whichever is longer, prior to screening for the study or the participant will participate simultaneously in another clinical study
  • Any evidence of pre existing viral resistance based on the presence of any major resistance associated mutation in the Screening result or, if known, in any historical resistance test result
  • Any verified Grade 4 laboratory abnormality. A single repeat test is allowed during the Screening period to verify a result
  • Any acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would preclude the participants participation in the study of an investigational compound
  • (ALT) >=5 times the (ULN) or ALT >=3xULN and >=1.5xULN (with >35% direct bilirubin)
  • of \<50 mL/min per 1.73 m\^2 via the chronic kidney disease epidemiology collaboration (CKD EPI) method
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
719 participants (actual)

Study arms

  • Experimental
    DTG + 3TC (50 mg+300 mg)

    Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated 300 mg 3TC tablet orally once daily upto 96 weeks; thereafter will receive DTG plus 3TC tablet upto Week 148 and will continue to receive this schedule until (i) DTG and 3TC are both locally approved for use as part of a dual regimen, and the single entities of DTG and 3TC are available to patients (e.g. through public health services), or (ii) the DTG/3TC FDC tablet, if required by local regulations, is available, , or (iii) the participant no longer derives clinical benefit, or (iv) the participant meets a protocol defined reason for discontinuation, or (v) development of the DTG plus 3TC dual regimen is terminated.

    Drug: Dolutegravir (DTG) · Drug: Lamivudine (3TC)

  • Active comparator
    DTG + TDF/FTC FDC (50 mg+300/200 mg)

    Eligible participants will receive one 50 mg tablet of DTG plus one overencapsulated TDF/ FTC FDC (300/200 mg) tablet orally once daily upto 96 weeks; thereafter will receive DTG plus TDF/FTC FDC tablets upto Week 148 (open-label randomised phase).

    Drug: Dolutegravir (DTG) · Drug: Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

Interventions

  • DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.

  • Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.

  • DrugTenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)

    Drug pages: Tenofovir · Emtricitabine

    Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.

07

What researchers measure

Primary outcomes

  1. Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel (CMH) weights. Intent-To-Treat Exposed (ITT-E) Population was used which comprised of all randomized participants who received at least one dose of study treatment. Percentage values are rounded to the nearest whole digit.

    Time frame: Week 48

Secondary outcomes

  1. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel weights. Percentage values are rounded to the nearest whole digit.

    Time frame: Week 24

  2. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel weights. Percentage values are rounded to the nearest whole digit.

    Time frame: Week 96

  3. Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144

    Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded to the nearest whole digit.

    Time frame: Week 144

  4. Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144

    Time of viral suppression is defined as the first viral load value \<50 c/mL. Nonparametric Kaplan-Meier method was performed. Participants who withdrew for any reason without being suppressed were censored at date of withdrawal. Participants who have not been withdrawn and have not had viral suppression at time of the analysis were censored at last viral load date. Confidence Interval (CI) was estimated using the Brookmeyer-Crowley method.

    Time frame: Up to Week 144

  5. CD4+ Cell Counts at Weeks 24 and 48

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry.

    Time frame: Weeks 24 and 48

  6. CD4+ Cell Counts at Week 96

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

    Time frame: Week 96

  7. CD4+ Cell Counts at Week 144

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

    Time frame: Week 144

  8. Changes From Baseline in CD4+ Cell Counts at Week 24 and 48

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is defined as the the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

    Time frame: Baseline (Day 1) and Weeks 24, 48

  9. Changes From Baseline in CD4+ Cell Counts at Week 96

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

    Time frame: Baseline (Day 1) and Week 96

  10. Changes From Baseline in CD4+ Cell Counts at Week 144

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

    Time frame: Baseline (Day 1) and Week 144

  11. Number of Participants With HIV-1 Disease Progression up to Week 144

    HIV-associated conditions were recorded during the study and was assessed according to the 2014 Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. Disease progressions summarize participants who had HIV infection stage 3 associated conditions or death. Indicators of clinical disease progression were defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrolment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrolment to Death.

    Time frame: Up to Week 144

  12. Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144

    Number of participants, who met confirmed virologic withdrawal (CVW) criteria, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI) and/or Nucleoside reverse transcriptase inhibitor (NRTI) was summarized. The Viral Genotypic Population comprised of all participants in the ITT-E population who have available on-treatment genotypic resistance data.

    Time frame: Up to Week 144

  13. Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144

    Number of participants, who meet CVW criteria, with treatment emergent phenotypic resistance to INSTI and/or NRTI were summarized. Assessment of antiviral activity of anti-retroviral therapy (ART) using phenotypic test results was interpreted through a proprietary algorithm (from Monogram Biosciences) and provides the overall susceptibility of the drug. Partially sensitive and resistant calls were considered resistant in this analysis. The Viral Phenotypic Population comprised of all participants in the ITT-E population who have available on-treatment phenotypic resistance data.

    Time frame: Up to Week 144

  14. Number of Participants With Any AE and SAE up to Week 148

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or protocol defined event associated with liver injury and impaired liver function were categorized as SAE. Safety Population was used which comprised of all participants who received at least one dose of study treatment.

    Time frame: Up to Week 148

  15. Number of Participants With AEs by Maximum Severity Grades up to Week 144

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

    Time frame: Up to Week 144

  16. Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 144

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5. (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with drug related AEs and drug related AEs by by maximum grade have been presented.

    Time frame: Up to Week 144

  17. Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144

    Blood samples were collected up to Week 144 for assessment of hemoglobin, leukocytes, neutrophils and platelets. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent hematology toxicities in any of the listed hematology parameters have been presented.

    Time frame: Up to Week 144

  18. Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144

    Blood samples were collected up to Week 144 for assessment of Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin, Carbon dioxide (CO2), Cholesterol, Creatine kinase (CK), Creatinine, Direct Bilirubin, Glomerular filtration rate (GFR) from creatinine adjusted for body surface area (BSA), Hypercalcemia, Hyperglycemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycemia, Hypokalemia, Hyponatremia, Low density lipid (LDL) Cholesterol, Lactate Dehydrogenase, Lipase, Phosphate, and Triglycerides. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent chemistry toxicities in any of the chemistry parameters have been presented

    Time frame: Up to Week 144

  19. Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. . Number of participants who discontinued treatment due to AEs have been reported.

    Time frame: Up to Week 24, Week 48 and Week 96

  20. Number of Participants Who Discontinue Treatment Due to AEs Over Week 144

    An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.

    Time frame: Up to Week 144

  21. Change From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Serum Cystatin C and Serum Retinol Binding Protein (RBP). Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  22. Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96

    Blood samples were collected to perform evaluation of renal inflammation biomarkers which included Serum Cystatin C . Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 96

  23. Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144

    Blood samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and at Week 144

  24. Change From Baseline in Renal Biomarker-Serum RBP at Week 96

    Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 96

  25. Change From Baseline in Renal Biomarker-Serum RBP at Week 144

    Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 144

  26. Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI (GFR-cystatin C adjusted)and Serum or Plasma GFR from creatinine adjusted using CKD-EPI. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  27. Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96

    Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 96

  28. Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144

    Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 144

  29. Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  30. Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 96

  31. Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 144

  32. Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Urine and Serum B2M, Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Statistical analysis of changes from baseline were performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios. Estimated ratio of geometric means (each visit over Baseline) and 95% confidence interval (CI) have been presented.

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  33. Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Statistical analysis of changes from baseline were performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios. Estimated ratio of geometric means (each visit over Baseline) and 95% confidence interval (CI) have been presented.

    Time frame: Baseline (Day 1) and Week 96

  34. Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144

    Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Urine and Serum B2M, Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Statistical analysis of changes from baseline were performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios. Estimated ratio of geometric means (each visit over Baseline) and 95% confidence interval (CI) have been presented.

    Time frame: Baseline (Day 1) and Week 144

  35. Change From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48

    Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  36. Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96

    Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 96

  37. Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144

    Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 144

  38. Change From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48

    Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  39. Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96

    Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 96

  40. Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144

    Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

    Time frame: Baseline (Day 1) and at Week 144

  41. Percentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48

    Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value is defined as the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value).

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  42. Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96

    Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and at Week 96

  43. Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144

    Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and at Week 144

  44. Percentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48

    Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value).

    Time frame: Baseline (Day 1) and at Weeks 24, 48

  45. Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96

    Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented.

    Time frame: Baseline (Day 1) and at Week 96

  46. Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144

    Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented.

    Time frame: Baseline (Day 1) and at Week 144

  47. Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48

    Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Weeks 24 and 48 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 48 or those who had Baseline lipids-lowering agents are not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded to the nearest whole digit.

    Time frame: Weeks 24 and Week 48

  48. Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96

    Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 96 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 96 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded to the nearest whole digit.

    Time frame: Week 96

  49. Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144

    Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 144 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 144 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded to the nearest whole digit.

    Time frame: Week 144

  50. Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24

    Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200, \>200), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian, Other). Percentage values are rounded to the nearest whole digit.

    Time frame: Week 24

  51. Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48

    Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200, \>200), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian, Other). Percentage values are rounded to the nearest whole digit.

    Time frame: Week 48

  52. Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96

    Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded to the nearest whole digit.

    Time frame: Week 96

  53. Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144

    Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded to the nearest whole digit.

    Time frame: Week 144

  54. Changes From Baseline in CD4+ Cell Counts at Week 24 by Subgroups

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age, Gender, and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

    Time frame: Baseline (Day 1) and Week 24

  55. Changes From Baseline in CD4+ Cell Counts at Week 48 by Subgroups

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from Analysis of Covariance (ANCOVA) model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

    Time frame: Baseline (Day 1) and Week 48

  56. Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

    Time frame: Baseline (Day 1) and Week 96

  57. Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups

    CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

    Time frame: Baseline (Day 1) and Week 144

  58. Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48

    EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment (Day 1) and change from Baseline=post-dose value minus Baseline value.

    Time frame: Baseline (Day 1) and Weeks 4, 24, 48

  59. Change From Baseline in EQ-5D-5L Utility Score at Week 96

    EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment (Day 1) and change from Baseline=post-dose value minus Baseline value.

    Time frame: Baseline (Day 1) and Week 96

  60. Change From Baseline in EQ-5D-5L Utility Score at Week 144

    EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment (Day 1) and change from Baseline=post-dose value minus Baseline value.

    Time frame: Baseline (Day 1) and Week 144

  61. Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24 48

    EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.

    Time frame: Baseline (Day 1) and Weeks 4, 24, 48

  62. Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96

    EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and Week 96

  63. Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144

    EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

    Time frame: Baseline (Day 1) and Week 144

08

Results

Posted Apr 18, 2019

Participant flow

This study is a randomized, double-blind, parallel-group, non-inferiority study. The study consisted of double blind, open label, and continuation phase.

Double-blind (Day 1 to Week 96)
Participant flow — Double-blind (Day 1 to Week 96)
MilestoneDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind PhaseDTG + 3TC - Open-label PhaseDTG + TDF/FTC - Open-label PhaseDTG + 3TC - Continuation Phase
Started359360000
Intent to treat exposed356358000
Completed301320000
Not completed5840000
Withdrew: Adverse event107000
Withdrew: Lack of efficacy42000
Withdrew: Protocol deviation66000
Withdrew: Protocol withdrawal criterion met26000
Withdrew: Lost to follow-up137000
Withdrew: Physician decision94000
Withdrew: Withdrawal by subject116000
Withdrew: Randomized but not treated32000
Open-label Phase (Week 96 to Week 148)
Participant flow — Open-label Phase (Week 96 to Week 148)
MilestoneDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind PhaseDTG + 3TC - Open-label PhaseDTG + TDF/FTC - Open-label PhaseDTG + 3TC - Continuation Phase
Started003013190
Completed002812940
Not completed0020250
Withdrew: Adverse event00360
Withdrew: Lack of efficacy00120
Withdrew: Protocol deviation00010
Withdrew: Protocol-specified withdrawal criterion met00210
Withdrew: Lost to follow-up00760
Withdrew: Physician decision00140
Withdrew: Withdrawal by subject00650
Continuation Phase(Week 148 to Week 280)
Participant flow — Continuation Phase(Week 148 to Week 280)
MilestoneDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind PhaseDTG + 3TC - Open-label PhaseDTG + TDF/FTC - Open-label PhaseDTG + 3TC - Continuation Phase
Started0000233
Completed0000212
Not completed000021
Withdrew: Adverse event00001
Withdrew: Protocol deviation00001
Withdrew: Lost to follow-up000010
Withdrew: Physician decision00002
Withdrew: Withdrawal by subject00007

Outcome measures

PrimaryPercentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using Food and Drug Administration (FDA) Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant antiretroviral therapy (ART) prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel (CMH) weights. Intent-To-Treat Exposed (ITT-E) Population was used which comprised of all randomized participants who received at least one dose of study treatment. Percentage values are rounded to the nearest whole digit.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 48
Percentage of participantsDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Percentage of Participants With Plasma Human Immunodeficiency Virus Type 1 (HIV-1) Ribonucleic Acid (RNA) <50 Copies/mL (c/mL) at Week 4890 (86.8 to 93.0)93 (90.0 to 95.4)
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Adjusted difference in proportion: -2.6 · 95% CI -6.7 to 1.5Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (\<=versus \[vs.\]\>100,000 c/mL) and cluster of differentiation 4+ (CD4+) cell count (\<= vs. \>200 cells per cubic millimeter).
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel weights. Percentage values are rounded to the nearest whole digit.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of participantsDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 2492 (89.7 to 95.2)93 (90.4 to 95.7)
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Adjusted difference in proportion: -0.4 · 95% CI -4.2 to 3.4Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (\<=vs.\>100,000 c/mL) and CD4+ cell count (\<= vs. \>200 cells per cubic millimeter).
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with Cochran-Mantel-Haenszel weights. Percentage values are rounded to the nearest whole digit.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 96
Percentage of participantsDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 9684 (80.5 to 88.1)89 (86.2 to 92.6)
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Adjusted difference in proportion: -4.9 · 95% CI -9.8 to 0.0Week 96. Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (\<= vs. \>100,000 c/mL) and CD4+ cell count (\<= vs. \>200 cells/mm\^3).
SecondaryPercentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144

Percentage of participants with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. This endpoint was analyzed using a stratified analysis with CMH weights. Percentage values are rounded to the nearest whole digit.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 144
Percentage of participantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Percentage of Participants With Plasma HIV-1 RNA <50 c/mL at Week 14479 (74.7 to 83.2)83 (78.8 to 86.6)
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Adjusted difference in proportion: -3.6 · 95% CI -9.4 to 2.1Week 144. Difference in proportion was based on CMH stratified analysis adjusting for Baseline stratification factors: Plasma HIV-1 RNA (\<= vs. \>100,000 c/mL) and CD4+ cell count (\<= vs. \>200 cells/mm\^3).
SecondaryTime to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144

Time of viral suppression is defined as the first viral load value \<50 c/mL. Nonparametric Kaplan-Meier method was performed. Participants who withdrew for any reason without being suppressed were censored at date of withdrawal. Participants who have not been withdrawn and have not had viral suppression at time of the analysis were censored at last viral load date. Confidence Interval (CI) was estimated using the Brookmeyer-Crowley method.

Time frame:
Up to Week 144
Reported as:
Median · Days
Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 144
DaysDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Time to Viral Suppression (HIV-1 RNA <50 c/mL) up to Week 14429.0 (29.0 to 53.0)29.0 (29.0 to 56.0)
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Generalized Wilcoxon procedure · p = 0.658 (The generalized Wilcoxon procedure was used to estimate a p-value for detecting a difference in cumulative incidence curves between treatment groups.) · Hazard ratio (hr): 1.00 · 95% CI 0.86 to 1.16Hazard ratios were estimated using the Cox proportional hazard regression model.
SecondaryCD4+ Cell Counts at Weeks 24 and 48

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry.

Time frame:
Weeks 24 and 48
Reported as:
Mean · Cells per cubic millimeter (cells/mm^3)
CD4+ Cell Counts at Weeks 24 and 48
Cells per cubic millimeter (cells/mm^3)DTG + 3TC Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Week 24, n=340,341655.3 ± 288.32632.8 ± 262.61
Week 48, n=324,334687.7 ± 275.47675.3 ± 274.46
SecondaryCD4+ Cell Counts at Week 96

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

Time frame:
Week 96
Reported as:
Mean · Cells per cubic millimeter (cells/mm^3)
CD4+ Cell Counts at Week 96
Cells per cubic millimeter (cells/mm^3)DTG + 3TC Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
CD4+ Cell Counts at Week 96732.8 ± 298.05711.5 ± 284.15
SecondaryCD4+ Cell Counts at Week 144

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry.

Time frame:
Week 144
Reported as:
Mean · Cells per cubic millimeter (cells/mm^3)
CD4+ Cell Counts at Week 144
Cells per cubic millimeter (cells/mm^3)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
CD4+ Cell Counts at Week 144767.8 ± 274.00758.2 ± 285.35
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 24 and 48

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is defined as the the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

Time frame:
Baseline (Day 1) and Weeks 24, 48
Reported as:
Mean · Cells per cubic millimeter
Changes From Baseline in CD4+ Cell Counts at Week 24 and 48
Cells per cubic millimeterDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Week 24, n=340,341192.2 ± 9.67175.1 ± 9.41
Week 48, n=324,334222.2 ± 9.87217.7 ± 10.64
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures (MMRM) · p = 0.206 · Mean difference (net): 17.1 · 95% CI -9.4 to 43.6Week 24. Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures (MMRM) · p = 0.754 · Mean difference (net): 4.6 · 95% CI -23.9 to 33.0Week 48. Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 96

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · Cells per cubic millimeter
Changes From Baseline in CD4+ Cell Counts at Week 96
Cells per cubic millimeterDTG + 3TC - Double-blind PhaseDTG + TDF/FTC-Double Blind Phase
Changes From Baseline in CD4+ Cell Counts at Week 96264.7 ± 11.32253.8 ± 11.40
Statistical analysis
  • DTG + 3TC - Double-blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures (MMRM) · p = 0.500 · Mean difference (net): 10.8 · 95% CI -20.7 to 42.4Week 96. Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 144

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+ cells. Analysis was performed by flow cytometry. Baseline value is defined as the the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented. Adjusted mean is the estimated mean change from Baseline at each visit in each arm calculated from a repeated measures model adjusting for the following covariates/factors: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction, and Baseline CD4+ cell count and visit interaction, with visit as the repeated factor.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Mean · Cells per cubic millimeter
Changes From Baseline in CD4+ Cell Counts at Week 144
Cells per cubic millimeterDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Changes From Baseline in CD4+ Cell Counts at Week 144301.8 ± 11.51303.2 ± 12.13
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures (MMRM) · p = 0.934 · Mean difference (net): -1.4 · 95% CI -34.2 to 31.5Week 144.Following covariates/factors were adjusted: treatment, visit, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, treatment and visit interaction and Baseline CD4+ cell count and visit interaction with visit as the repeated factor.
SecondaryNumber of Participants With HIV-1 Disease Progression up to Week 144

HIV-associated conditions were recorded during the study and was assessed according to the 2014 Centers for Disease Control and Prevention (CDC) Classification System for HIV Infection in Adults. Disease progressions summarize participants who had HIV infection stage 3 associated conditions or death. Indicators of clinical disease progression were defined as: CDC Category Stage 1 at enrollment to Stage 3 event; CDC Category Stage 2 at enrolment to Stage 3 event; CDC Category Stage 3 at enrollment to New Stage 3 Event; CDC Category Stage 1, 2 or 3 at enrolment to Death.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With HIV-1 Disease Progression up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
No HIV-1 disease progression352356
From CDC Stage 1 to CDC Stage 3 Event00
From CDC Stage 2 to CDC Stage 3 Event22
From CDC Stage 3 to New CDC Stage 3 Event10
From CDC Stage 1, 2 or 3 to Death10
SecondaryNumber of Participants With Treatment-emergent Genotypic Resistance up to Week 144

Number of participants, who met confirmed virologic withdrawal (CVW) criteria, with treatment emergent genotypic resistance to Integrase strand transfer inhibitor (INSTI) and/or Nucleoside reverse transcriptase inhibitor (NRTI) was summarized. The Viral Genotypic Population comprised of all participants in the ITT-E population who have available on-treatment genotypic resistance data.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Genotypic Resistance up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
INSTI Mutations00
Major mutations of NRTI00
SecondaryNumber of Participants With Treatment-emergent Phenotypic Resistance up to Week 144

Number of participants, who meet CVW criteria, with treatment emergent phenotypic resistance to INSTI and/or NRTI were summarized. Assessment of antiviral activity of anti-retroviral therapy (ART) using phenotypic test results was interpreted through a proprietary algorithm (from Monogram Biosciences) and provides the overall susceptibility of the drug. Partially sensitive and resistant calls were considered resistant in this analysis. The Viral Phenotypic Population comprised of all participants in the ITT-E population who have available on-treatment phenotypic resistance data.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Phenotypic Resistance up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
INSTI, DTG, Sensitive, n=,5,454
INSTI, DTG, Resistant, n=5,400
INSTI, EGV, Sensitive, n=5,454
INSTI, EGV, Resistant, n=5,400
INSTI, RAL, Sensitive, n=5,454
INSTI, RAL, Resistant, n=5,400
NRTI, 3TC, Sensitive, n=5,555
NRTI, 3TC, Resistant, n=5,500
NRTI, ABC, Sensitive, n=5,555
NRTI, ABC, Resistant, n=5,500
NRTI, AZT, Sensitive, n=5,555
NRTI, AZT, Resistant, n=5,500
NRTI, D4T, Sensitive, n=5,555
NRTI, D4T, Resistant, n=5,500
NRTI, DDI, Sensitive, n=5,555
NRTI, DDI, Resistant, n=5,500
NRTI, FTC, Sensitive, n=5,555
NRTI, FTC, Resistant, n=5,500
NRTI, TDF, Sensitive, n=5,555
NRTI, TDF, Resistant, n=5,500
SecondaryNumber of Participants With Any AE and SAE up to Week 148

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment that may not be immediately life-threatening or result in death or hospitalization but may jeopardize the participant or may require medical or surgical intervention or protocol defined event associated with liver injury and impaired liver function were categorized as SAE. Safety Population was used which comprised of all participants who received at least one dose of study treatment.

Time frame:
Up to Week 148
Reported as:
Count of participants · Participants
Number of Participants With Any AE and SAE up to Week 148
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Any AE307316
Any SAE3738
SecondaryNumber of Participants With AEs by Maximum Severity Grades up to Week 144

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with adverse events by maximum grade have been presented.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With AEs by Maximum Severity Grades up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Grade 1 AEs3335
Grade 2 AEs229242
Grade 3 AEs3734
Grade 4 AEs75
Grade 5 AEs10
SecondaryNumber of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 144

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. AEs were evaluated by the investigator and graded according to the DAIDS toxicity scales from Grade 1 to 5. (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening, 5=Death). The higher the grade, the more severe the symptoms. Number of participants with drug related AEs and drug related AEs by by maximum grade have been presented.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With Any Drug Related AEs and Drug Related AEs by Maximum Grade up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Any drug related AE77101
Drug related AEs with maximum toxicity Grade 15170
Drug related AEs with maximum toxicity Grade 21928
Drug related AEs with maximum toxicity Grade 373
Drug related AEs with maximum toxicity Grade 400
Drug related AEs with maximum toxicity Grade 500
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144

Blood samples were collected up to Week 144 for assessment of hemoglobin, leukocytes, neutrophils and platelets. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent hematology toxicities in any of the listed hematology parameters have been presented.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Hematology Toxicities up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Hemoglobin, Grades 1 to 497
Hemoglobin, Grades 2 to 411
Hemoglobin, Grades 3 to 400
Hemoglobin, Grade 186
Hemoglobin, Grade 211
Hemoglobin, Grade 300
Hemoglobin, Grade 400
Leukocytes, Grades 1 to 4163
Leukocytes, Grades 2 to 442
Leukocytes, Grades 3 to 400
Leukocytes, Grade 1121
Leukocytes, Grade 242
Leukocytes, Grade 300
Leukocytes, Grade 400
Neutrophils, Grades 1 to 42518
Neutrophils, Grades 2 to 41911
Neutrophils, Grades 3 to 476
Neutrophils, Grade 167
Neutrophils, Grade 2125
Neutrophils, Grade 355
Neutrophils, Grade 421
Platelets, Grades 1 to 41411
Platelets, Grades 2 to 484
Platelets, Grades 3 to 411
Platelets, Grade 167
Platelets, Grade 273
Platelets, Grade 301
Platelets, Grade 410
SecondaryNumber of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144

Blood samples were collected up to Week 144 for assessment of Alanine Aminotransferase (ALT), Albumin, Alkaline Phosphatase (ALP), Aspartate aminotransferase (AST), Bilirubin, Carbon dioxide (CO2), Cholesterol, Creatine kinase (CK), Creatinine, Direct Bilirubin, Glomerular filtration rate (GFR) from creatinine adjusted for body surface area (BSA), Hypercalcemia, Hyperglycemia, Hyperkalemia, Hypernatremia, Hypocalcemia, Hypoglycemia, Hypokalemia, Hyponatremia, Low density lipid (LDL) Cholesterol, Lactate Dehydrogenase, Lipase, Phosphate, and Triglycerides. Any abnormality was graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Only those participants with maximum post-Baseline emergent chemistry toxicities in any of the chemistry parameters have been presented

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants With Maximum Post-Baseline Emergent Chemistry Toxicities up to Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
ALT, Grades 1 to 45581
ALT, Grades 2 to 42325
ALT, Grades 3 to 4149
ALT, Grade 13256
ALT, Grade 2916
ALT, Grade 374
ALT, Grade 475
Albumin, Grades 1 to 411
Albumin, Grades 2 to 410
Albumin, Grades 3 to 400
Albumin, Grade 101
Albumin, Grade 210
Albumin, Grade 300
Albumin, Grade 400
ALP, Grades 1 to 4810
ALP, Grades 2 to 431
ALP, Grades 3 to 400
ALP, Grade 159
ALP, Grade 231
ALP, Grade 300
ALP, Grade 400
AST, Grades 1 to 45279
AST, Grades 2 to 42731
AST, Grades 3 to 4813
AST, Grade 12548
AST, Grade 21918
AST, Grade 369
AST, Grade 424
Bilirubin, Grades 1 to 44251
Bilirubin, Grades 2 to 41417
Bilirubin, Grades 3 to 444
Bilirubin, Grade 12834
Bilirubin, Grade 21013
Bilirubin, Grade 324
Bilirubin, Grade 420
CO2, Grades 1 to 4126116
CO2, Grades 2 to 489
CO2, Grades 3 to 400
CO2, Grade 1118107
CO2, Grade 289
CO2, Grade 300
CO2, Grade 400
Cholesterol, Grades 1 to 47740
Cholesterol, Grades 2 to 42413
Cholesterol, Grades 3 to 401
Cholesterol, Grade 15327
Cholesterol, Grade 22412
Cholesterol, Grade 301
Cholesterol, Grade 400
CK, Grades 1 to 47675
CK, Grades 2 to 44352
CK, Grades 3 to 42636
CK, Grade 13323
CK, Grade 21716
CK, Grade 31521
CK, Grade 41115
Creatinine, Grades 1 to 42131
Creatinine, Grades 2 to 413
Creatinine, Grades 3 to 402
Creatinine, Grade 12028
Creatinine, Grade 211
Creatinine, Grade 302
Creatinine, Grade 400
Direct Bilirubin, Grades 1 to 41413
Direct Bilirubin, Grades 2 to 41413
Direct Bilirubin, Grades 3 to 41413
Direct Bilirubin, Grade 100
Direct Bilirubin, Grade 200
Direct Bilirubin, Grade 31413
Direct Bilirubin, Grade 400
GFR from creatinine adjusted for BSA Grades 1 to 4185226
GFR from creatinine adjusted for BSA Grades 2 to 4185226
GFR from creatinine adjusted for BSA Grades 3 to 41327
GFR from creatinine adjusted for BSA, Grade 100
GFR from creatinine adjusted for BSA, Grade 2172199
GFR from creatinine adjusted for BSA Grades 31325
GFR from creatinine adjusted for BSA, Grade 402
Hypercalcaemia, Grades 1 to 474
Hypercalcaemia, Grades 2 to 400
Hypercalcaemia, Grades 3 to 400
Hypercalcaemia, Grade 174
Hypercalcaemia, Grade 200
Hypercalcaemia, Grade 300
Hypercalcaemia, Grade 400
Hyperglycemia, Grades 1 to 49181
Hyperglycemia, Grades 2 to 43825
Hyperglycemia, Grades 3 to 432
Hyperglycemia, Grade 15356
Hyperglycemia, Grade 23523
Hyperglycemia, Grade 332
Hyperglycemia, Grade 400
Hyperkalemia, Grades 1 to 414
Hyperkalemia, Grades 2 to 401
Hyperkalemia, Grades 3 to 401
Hyperkalemia, Grade 113
Hyperkalemia, Grade 200
Hyperkalemia, Grade 300
Hyperkalemia, Grade 401
Hypernatremia, Grades 1 to 463
Hypernatremia, Grades 2 to 400
Hypernatremia, Grades 3 to 400
Hypernatremia, Grade 163
Hypernatremia, Grade 200
Hypernatremia, Grade 300
Hypernatremia, Grade 400
Hypocalcaemia, Grades 1 to 41413
Hypocalcaemia, Grades 2 to 443
Hypocalcaemia, Grades 3 to 401
Hypocalcaemia, Grade 11010
Hypocalcaemia, Grade 242
Hypocalcaemia, Grade 301
Hypocalcaemia, Grade 400
Hypoglycemia, Grades 1 to 42217
Hypoglycemia, Grades 2 to 483
Hypoglycemia, Grades 3 to 421
Hypoglycemia, Grade 11414
Hypoglycemia, Grade 262
Hypoglycemia, Grade 310
Hypoglycemia, Grade 411
Hypokalemia, Grades 1 to 467
Hypokalemia, Grades 2 to 401
Hypokalemia, Grades 3 to 400
Hypokalemia, Grade 166
Hypokalemia, Grade 201
Hypokalemia, Grade 300
Hypokalemia, Grade 400
Hyponatremia, Grades 1 to 42528
Hyponatremia, Grades 2 to 420
Hyponatremia, Grades 3 to 400
Hyponatremia, Grade 12328
Hyponatremia, Grade 220
Hyponatremia, Grade 300
Hyponatremia, Grade 400
LDL Cholesterol, Grades 1 to 45735
LDL Cholesterol, Grades 2 to 41714
LDL Cholesterol, Grades 3 to 454
LDL Cholesterol, Grade 14021
LDL Cholesterol, Grade 21210
LDL Cholesterol, Grade 354
LDL Cholesterol, Grade 400
Lactate Dehydrogenase, Grades 1 to 435
Lactate Dehydrogenase, Grades 2 to 401
Lactate Dehydrogenase, Grades 3 to 400
Lactate Dehydrogenase, Grade 134
Lactate Dehydrogenase, Grade 201
Lactate Dehydrogenase, Grade 300
Lactate Dehydrogenase, Grade 400
Lipase, Grades 1 to 46580
Lipase, Grades 2 to 43549
Lipase, Grades 3 to 41018
Lipase, Grade 13031
Lipase, Grade 22531
Lipase, Grade 3810
Lipase, Grade 428
Phosphate, Grades 1 to 47068
Phosphate, Grades 2 to 43547
Phosphate, Grades 3 to 426
Phosphate, Grade 13521
Phosphate, Grade 23341
Phosphate, Grade 326
Phosphate, Grade 400
Triglycerides, Grades 1 to 48062
Triglycerides, Grades 2 to 41214
Triglycerides, Grades 3 to 473
Triglycerides, Grade 16848
Triglycerides, Grade 2511
Triglycerides, Grade 362
Triglycerides, Grade 411
SecondaryNumber of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. . Number of participants who discontinued treatment due to AEs have been reported.

Time frame:
Up to Week 24, Week 48 and Week 96
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Treatment Due to AEs Over Weeks 24, 48, 96
ParticipantsDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Up to Week 2464
Up to Week 4878
Up to Week 961411
SecondaryNumber of Participants Who Discontinue Treatment Due to AEs Over Week 144

An AE is any untoward medical occurrence in a clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Number of participants who discontinued treatment due to AEs have been reported.

Time frame:
Up to Week 144
Reported as:
Count of participants · Participants
Number of Participants Who Discontinue Treatment Due to AEs Over Week 144
ParticipantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Number of Participants Who Discontinue Treatment Due to AEs Over Week 1441817
SecondaryChange From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Serum Cystatin C and Serum Retinol Binding Protein (RBP). Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Mean · Milligrams per Liter (mg/L)
Change From Baseline in Renal Biomarkers-Serum Cystatin C and Serum Retinol Binding Protein (RBP) at Weeks 24, 48
Milligrams per Liter (mg/L)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Serum Cystatin C, Week 24, n=338, 336-0.05 ± 0.007-0.03 ± 0.007
Serum Cystatin C, Week 48, n=324, 332-0.07 ± 0.007-0.04 ± 0.006
Serum RBP, Week 24, n=332, 3341.6 ± 0.411.9 ± 0.51
Serum RBP, Week 48, n=322, 3320.5 ± 0.470.6 ± 0.46
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.025 · Mean difference (net): -0.02 · 95% CI -0.04 to 0.00Serum Cystatin C, Week 24
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.001 · Mean difference (net): -0.03 · 95% CI -0.05 to -0.01Serum Cystatin C, Week 48
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.683 · Mean difference (net): -0.3 · 95% CI -1.6 to 1.0Serum RBP, Week 24
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.930 · Mean difference (net): -0.1 · 95% CI -1.4 to 1.2Serum RBP, Week 48
SecondaryChange From Baseline in Renal Biomarker-Serum Cystatin C at Week 96

Blood samples were collected to perform evaluation of renal inflammation biomarkers which included Serum Cystatin C . Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Milligrams per Liter (mg/L)
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96
Milligrams per Liter (mg/L)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 96-0.11 ± 0.006-0.09 ± 0.006
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.009 · Mean difference (net): -0.02 · 95% CI -0.04 to -0.01Week 96. Serum Cystatin C.
SecondaryChange From Baseline in Renal Biomarker-Serum Cystatin C at Week 144

Blood samples were collected to perform evaluation of renal biomarkers which included Serum Cystatin C. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Milligrams per Liter (mg/L)
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144
Milligrams per Liter (mg/L)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Renal Biomarker-Serum Cystatin C at Week 144-0.12 ± 0.006-0.11 ± 0.007
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = 0.108 · Mean difference (net): -0.01 · 95% CI -0.03 to -0.00Week 144. Serum Cystatin C.
SecondaryChange From Baseline in Renal Biomarker-Serum RBP at Week 96

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Microgram per millimoles (ug/mmol)
Change From Baseline in Renal Biomarker-Serum RBP at Week 96
Microgram per millimoles (ug/mmol)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Change From Baseline in Renal Biomarker-Serum RBP at Week 961.535 ± 8.58727.704 ± 41.9650
SecondaryChange From Baseline in Renal Biomarker-Serum RBP at Week 144

Blood and/or urine samples were collected to perform evaluation of renal biomarkers which included Serum RBP. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Microgram per millimoles (ug/mmol)
Change From Baseline in Renal Biomarker-Serum RBP at Week 144
Microgram per millimoles (ug/mmol)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Renal Biomarker-Serum RBP at Week 1441.760 ± 5.79098.855 ± 35.5147
SecondaryChange From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI (GFR-cystatin C adjusted)and Serum or Plasma GFR from creatinine adjusted using CKD-EPI. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Mean · Milliliter/minute/1.73*meter^2
Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) and Serum or Plasma GFR From Creatinine Adjusted Using CKD-EPI at Weeks 24, 48
Milliliter/minute/1.73*meter^2DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
GFR-cystatin C adjusted, Week 24, n=338, 3364.4 ± 0.632.2 ± 0.60
GFR-cystatin C adjusted, Week 48, n=324, 3327.0 ± 0.604.1 ± 0.59
GFR-creatinine adjusted, Week 24, n=340, 341-13.5 ± 0.59-16.7 ± 0.56
GFR-creatinine adjusted, Week 48, n=326,335-12.1 ± 0.56-15.6 ± 0.55
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.011 · Mean difference (net): 2.2 · 95% CI 0.5 to 4.0GFR-cystatin C adjusted, Week 24
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): 2.8 · 95% CI 1.2 to 4.5GFR-cystatin C adjusted, Week 48
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): 3.2 · 95% CI 1.6 to 4.8GFR-creatinine adjusted, Week 24
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): 3.5 · 95% CI 2.0 to 5.1GFR- creatinine adjusted, Week 48
SecondaryChange From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96

Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Milliliter/minute/1.73*meter^2
Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 96
Milliliter/minute/1.73*meter^2DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
GFR Cystatin C adjusted, Week 9611.3 ± 14.549.3 ± 13.78
GFR creatinine adjusted, Week 96-15.3 ± 11.50-19.0 ± 11.25
SecondaryChange From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144

Blood samples were collected to perform evaluation of renal biomarkers which included Serum GFR from cystatin C adjusted using CKD-EPI and Serum or Plasma GFR from creatinine adjusted for BSA using CKD-EPI. Baseline value is the latest pre-dose Assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Biomarkers were adjusted for treatment, visit, Baseline plasma HIV-1 RNA, baseline CD4+ cell count, age, sex, race, presence of diabetes mellitus, presence of hypertension, Baseline biomarker value, treatment and visit interaction, and Baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Milliliter/minute/1.73*meter^2
Change From Baseline in Renal Biomarkers-Serum GFR From Cystatin C Adjusted Using CKD-EPI and Serum or Plasma GFR From Creatinine Adjusted for BSA Using CKD-EPI Method at Week 144
Milliliter/minute/1.73*meter^2DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
GFR Cystatin C adjusted, Week 144, n=283,29813.0 ± 13.6412.1 ± 15.24
GFR creatinine adjusted, Week 144, n=271, 289-16.7 ± 11.65-19.3 ± 11.07
SecondaryChange From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48

Blood and/or urine were collected to perform evaluation of renal inflammation biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Mean · Micromoles per Liter (umol/L)
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Weeks 24, 48
Micromoles per Liter (umol/L)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Serum or Plasma Creatinine, Week 24, n=340, 34311.88 ± 0.51015.07 ± 0.520
Serum or Plasma Creatinine, Week 48, n=326, 33510.39 ± 0.46613.61 ± 0.480
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -3.19 · 95% CI -4.62 to -1.75Week 24
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -3.22 · 95% CI -4.54 to -1.91Week 48
SecondaryChange From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96

Blood and/or urine were collected to perform evaluation of renal inflammation biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Micromoles per Liter (umol/L)
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 96
Micromoles per Liter (umol/L)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 9612.75 ± 0.62316.10 ± 0.539
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -3.34 · 95% CI -4.96 to -1.72Week 96. Serum or Plasma creatinine
SecondaryChange From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144

Blood and/or urine were collected to perform evaluation of renal inflammation biomarker which included Serum or Plasma Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), presence of diabetes mellitus (factor), presence of hypertension (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Micromoles per Liter (umol/L)
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 144
Micromoles per Liter (umol/L)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Renal Biomarker-Serum or Plasma Creatinine at Week 14412.89 ± 0.58315.87 ± 0.560
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -2.98 · 95% CI -4.57 to -1.40Week 144. Serum or Plasma creatinine
SecondaryRatio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Urine and Serum B2M, Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Statistical analysis of changes from baseline were performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios. Estimated ratio of geometric means (each visit over Baseline) and 95% confidence interval (CI) have been presented.

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Geometric mean · Ratio
Ratio to Baseline in Renal Biomarkers-Urine and Serum Beta-2 Microglobulin (B2M), Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine at Weeks 24, 48
RatioDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Serum B2M, Week 24, n=338, 3350.798 (0.779 to 0.817)0.872 (0.856 to 0.890)
Serum B2M, Week 48, n=324, 3320.806 (0.790 to 0.823)0.892 (0.876 to 0.908)
Urine B2M, Week 24, n=121, 950.887 (0.756 to 1.039)1.351 (1.060 to 1.722)
Urine B2M, Week 48, n=119, 1030.900 (0.792 to 1.022)1.338 (1.148 to 1.560)
Urine Albumin/Creatinine, Week 24, n=254, 2521.014 (0.927 to 1.109)1.050 (0.964 to 1.144)
Urine Albumin/Creatinine , Week 48, n=237, 2440.934 (0.857 to 1.017)1.048 (0.968 to 1.134)
Urine B2M/Urine Creatinine, Week 24, n=121, 950.852 (0.737 to 0.985)1.331 (1.071 to 1.655)
Urine B2M/Urine Creatinine, Week 48, n=114, 1000.888 (0.777 to 1.015)1.278 (1.119 to 1.458)
Urine Phosphate, Week 24, n=330, 3321.115 (1.025 to 1.212)1.012 (0.934 to 1.095)
Urine Phosphate, Week 48, n=316, 3301.061 (0.983 to 1.145)1.075 (0.996 to 1.159)
Urine Protein/Creatinine, Week 24, n=269, 2650.850 (0.806 to 0.895)1.016 (0.960 to 1.075)
Urine Protein/Creatinine, Week 48, n=252, 2690.879 (0.838 to 0.922)1.061 (1.009 to 1.115)
Urine RBP 4, Week 24, n=332, 3300.934 (0.842 to 1.036)1.073 (0.951 to 1.209)
Urine RBP 4, Week 48, n=318, 3281.115 (1.009 to 1.233)1.490 (1.332 to 1.667)
Urine RBP 4/Urine Creatinine, Week 24, n=329, 3300.919 (0.846 to 0.998)1.110 (1.003 to 1.228)
Urine RBP 4/Urine Creatinine, Week 48, n=304, 3181.147 (1.060 to 1.241)1.500 (1.367 to 1.646)
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.915 · 95% CI 0.887 to 0.943Week 24. Serum B2M
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.904 · 95% CI 0.880 to 0.929Week 48. Serum B2M
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.005 · Ratio of geometric means: 0.656 · 95% CI 0.491 to 0.877Week 24. Urine B2M
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.672 · 95% CI 0.551 to 0.821Week 48. Urine B2M
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.575 · Ratio of geometric means: 0.965 · 95% CI 0.853 to 1.092Week 24. Urine Albumin/Creatinine
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.051 · Ratio of geometric means: 0.891 · 95% CI 0.793 to 1.001Week 48. Urine Albumin/Creatinine
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.640 · 95% CI 0.493 to 0.831Week 24. Urine B2M/Urine Creatinine
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.695 · 95% CI 0.576 to 0.839Week 48. Urine B2M/Urine Creatinine
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.099 · Ratio of geometric means: 1.102 · 95% CI 0.982 to 1.237Week 24. Urine Phosphate
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.816 · Ratio of geometric means: 0.987 · 95% CI 0.886 to 1.100Week 48. Urine Phosphate
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.836 · 95% CI 0.774 to 0.904Week 24. Urine Protein/Creatinine
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.829 · 95% CI 0.773 to 0.888Week 48. Urine Protein/Creatinine
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.087 · Ratio of geometric means: 0.871 · 95% CI 0.743 to 1.020Week 24. Urine RBP 4
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.748 · 95% CI 0.644 to 0.870Week 48. Urine RBP 4
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.005 · Ratio of geometric means: 0.828 · 95% CI 0.727 to 0.944Week 24. Urine RBP 4/Urine Creatinine
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.765 · 95% CI 0.677 to 0.864Week 48. Urine RBP 4/Urine Creatinine
SecondaryRatio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Statistical analysis of changes from baseline were performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios. Estimated ratio of geometric means (each visit over Baseline) and 95% confidence interval (CI) have been presented.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Geometric mean · Ratio
Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 96
RatioDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Urine Albumin/Creatinine, Week 96, n=222, 2430.924 (0.847 to 1.008)1.101 (1.008 to 1.202)
Urine B2M/Urine Creatinine , Week 96, n=107, 1040.794 (0.720 to 0.877)1.441 (1.193 to 1.740)
Urine Phosphate, Week 96, n=292, 3161.113 (1.021 to 1.214)1.066 (0.984 to 1.155)
Urine Protein/Creatinine, Week 96, n=238, 2580.868 (0.818 to 0.920)1.053 (1.004 to 1.105)
Urine RBP 4/Urine Creatinine, Week 96, n=289, 3111.310 (1.207 to 1.420)1.771 (1.604 to 1.955)
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.006 · Ratio of geometric means: 0.839 · 95% CI 0.742 to 0.950Week 96. Urine Albumin/Creatinine.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.551 · 95% CI 0.445 to 0.682Week 96. Urine B2M/Urine Creatinine.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.467 · Ratio of geometric means: 1.045 · 95% CI 0.928 to 1.175Week 96. Urine Phosphate.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.824 · 95% CI 0.764 to 0.889Week 96. Urine Protein/Creatinine.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.740 · 95% CI 0.651 to 0.840Week 96. Urine RBP 4/Urine Creatinine
SecondaryRatio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144

Blood and/or urine were collected to perform evaluation of renal inflammation biomarkers which included Urine and Serum B2M, Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine, Urine RBP 4 and Urine RBP 4/Urine Creatinine. Baseline value is defined as the latest pre-dose assessment (Day 1). Ratio to Baseline was calculated as ratio of post-dose visit value over Baseline value. Statistical analysis of changes from baseline were performed on log-transformed data. Results were transformed back via exponential transformation such that treatment comparisons are assessed via odds ratios. Estimated ratio of geometric means (each visit over Baseline) and 95% confidence interval (CI) have been presented.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Geometric mean · Ratio
Ratio to Baseline in Renal Biomarkers- Urine Albumin/Creatinine, Urine B2M/Urine Creatinine, Urine Phosphate, Urine Protein/Creatinine and Urine RBP 4/Urine Creatinine at Week 144
RatioDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Urine Albumin/Creatinine , Week 144, n=207, 2121.050 (0.954 to 1.155)1.146 (1.039 to 1.264)
Urine B2M/Urine Creatinine , Week 144, n=100, 1020.751 (0.679 to 0.830)1.518 (1.281 to 1.799)
Urine Phosphate, Week 144, n=274, 2941.040 (0.954 to 1.133)0.955 (0.879 to 1.037)
Urine Protein/Creatinine , Week 144, n=225,2320.988 (0.932 to 1.047)1.210 (1.144 to 1.280)
Urine RBP 4/Urine Creatinine, Week 144, n=276, 2921.648 (1.550 to 1.752)2.425 (2.208 to 2.663)
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = 0.205 · Ratio of geometric means: 0.916 · 95% CI 0.799 to 1.050Week 144. Urine Albumin/Creatinine.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.495 · 95% CI 0.406 to 0.603Week 144. Urine B2M/Urine Creatinine.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = 0.160 · Ratio of geometric means: 1.089 · 95% CI 0.967 to 1.226Week 144. Urine Phosphate.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.817 · 95% CI 0.753 to 0.885Week 144. Urine Protein/Creatinine.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = <0.001 · Ratio of geometric means: 0.679 · 95% CI 0.607 to 0.760Week 144. Urine RBP 4/Urine Creatinine
SecondaryChange From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48

Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Mean · Micrograms per Liter (ug/L)
Change From Baseline in Bone Biomarkers-Serum Bone Specific Alkaline Phosphatase (Bone-ALP), Serum Osteocalcin, Serum Procollagen 1 N-Terminal Propeptide (PINP) and Serum Type I Collagen C-Telopeptides (CTX-1) at Weeks 24, 48
Micrograms per Liter (ug/L)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Bone-ALP, Week 24, n=334, 3320.91 ± 0.1793.13 ± 0.199
Bone-ALP, Week 48, n=321, 3311.21 ± 0.1933.79 ± 0.239
Serum Osteocalcin, Week 24, n=335, 3342.56 ± 0.3416.74 ± 0.347
Serum Osteocalcin, Week 48, n=322, 3300.78 ± 0.3116.01 ± 0.400
PINP, Week 24, n=337, 3364.5 ± 0.9118.3 ± 1.06
PINP, Week 48, n=321, 3340.5 ± 0.8313.1 ± 0.84
CTX-1, Week 24, n=337, 3340.1192 ± 0.013040.2820 ± 0.01472
CTX-1, Week 48, n=323, 3310.1338 ± 0.012580.3352 ± 0.01885
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -2.23 · 95% CI -2.75 to -1.70Week 24. Bone ALP
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -2.58 · 95% CI -3.19 to -1.98Week 48. Bone ALP
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -4.19 · 95% CI -5.15 to -3.23Week 28. Serum Osteocalcin
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -5.23 · 95% CI -6.22 to -4.23Week 48. Serum Osteocalcin
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -13.8 · 95% CI -16.5 to -11.1Week 24. Serum PINP
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -12.6 · 95% CI -15.0 to -10.3Week 48. Serum PINP
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -0.1628 · 95% CI -0.2015 to -0.1241Week 24. CTX-1
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -0.2015 · 95% CI -0.2460 to -0.1569Week 48. CTX-1
SecondaryChange From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96

Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Micrograms per Liter (ug/L)
Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 96
Micrograms per Liter (ug/L)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Bone-ALP, Week 96, n=296, 3170.30 ± 0.1912.37 ± 0.216
Serum Osteocalcin, Week 96, n=297, 3200.40 ± 0.3454.57 ± 0.391
PINP, Week 96, n=297, 31915.0 ± 1.6328.3 ± 1.50
CTX-1, Week 96, n=297, 3150.1351 ± 0.015800.2943 ± 0.01916
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -2.06 · 95% CI -2.63 to -1.50Week 96, Bone ALP
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -4.17 · 95% CI -5.20 to -3.14Week 96, Serum Osteocalcin
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -13.3 · 95% CI -17.6 to -8.9Week 96, Serum PINP
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -0.1592 · 95% CI -0.2080 to -0.1104Week 96, CTX-1
SecondaryChange From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144

Blood samples were collected to perform evaluation of bone biomarkers which included bone-ALP, Serum Osteocalcin, PINP and CTX-1. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Micrograms per Liter (ug/L)
Change From Baseline in Bone Biomarkers-Serum Bone-ALP, Serum Osteocalcin, Serum PINP and Serum Type I CTX-1 at Week 144
Micrograms per Liter (ug/L)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Bone-ALP, Week 144, n=281, 295-0.25 ± 0.1721.43 ± 0.217
Serum Osteocalcin, Week 144, n=281, 2990.29 ± 0.3743.21 ± 0.403
PINP, Week 144, n=281,2994.6 ± 1.0413.8 ± 1.14
CTX-1, Week 144, n=281, 2960.0750 ± 0.011500.2164 ± 0.01407
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -1.68 · 95% CI -2.23 to -1.14Week 144, Bone ALP
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -2.91 · 95% CI -4.00 to -1.83Week 144, Serum Osteocalcin
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -9.2 · 95% CI -12.3 to -6.2Week 144, Serum PINP
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -0.1414 · 95% CI -0.1771 to -0.1056Week 144, CTX-1
SecondaryChange From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48

Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Mean · Nanomoles per Liter (nmol/L)
Change From Baseline in Bone Biomarker-Serum Vitamin D at Weeks 24, 48
Nanomoles per Liter (nmol/L)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Serum Vitamin D, Week 24, n=337, 3375.9 ± 1.1512.4 ± 1.33
Serum Vitamin D, Week 48, n=322, 333-3.1 ± 0.893.1 ± 1.10
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -6.5 · 95% CI -9.9 to -3.0Week 24
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = <0.001 · Mean difference (net): -6.2 · 95% CI -9.0 to -3.4Week 48
SecondaryChange From Baseline in Bone Biomarker-Serum Vitamin D at Week 96

Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Nanomoles per Liter (nmol/L)
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96
Nanomoles per Liter (nmol/L)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 96-2.2 ± 1.050.7 ± 1.04
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mixed Model Repeated Measures · p = 0.048 · Mean difference (net): -2.9 · 95% CI -5.8 to 0.0Week 96
SecondaryChange From Baseline in Bone Biomarker-Serum Vitamin D at Week 144

Blood samples were collected to perform evaluation of bone biomarker serum vitamin D. Baseline value is defined as the latest pre-dose assessment (Day 1). Change from Baseline was calculated as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented. Adjusted mean is the estimated mean change from baseline at each visit in each arm calculated from a repeated measures model adjusting for: treatment, visit, baseline plasma HIV-1 RNA (factor), baseline CD4+ cell count (factor), age, sex (factor), race (factor), BMI (factor), smoking status (factor), current Vitamin D use (factor), baseline biomarker value, treatment and visit interaction, and baseline biomarker value and visit interaction; with visit as the repeated factor.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Nanomoles per Liter (nmol/L)
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144
Nanomoles per Liter (nmol/L)DTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Bone Biomarker-Serum Vitamin D at Week 144-2.0 ± 1.162.9 ± 1.28
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mixed Model Repeated Measures · p = 0.004 · Mean difference (net): -4.9 · 95% CI -8.3 to -1.6Week 144
SecondaryPercentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48

Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value is defined as the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value).

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Mean · Percentage change
Percentage Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Weeks 24, 48
Percentage changeDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Serum or Plasma Cholesterol, Week 24, n=294, 2979.4 ± 17.44-4.7 ± 16.12
Serum or Plasma Cholesterol, Week 48, n=280, 28910.5 ± 18.89-2.4 ± 17.14
HDL Cholesterol, Direct, Week 24, n=294, 29716.4 ± 22.583.4 ± 21.55
HDL Cholesterol, Direct, Week 48, n=280, 28915.0 ± 25.075.0 ± 33.04
LDL Cholesterol, Week 24, n=294, 29712.4 ± 45.05-8.1 ± 23.70
LDL Cholesterol, Week 48, n=280, 28914.8 ± 48.74-4.0 ± 24.06
Triglycerides ,Week 24, n=294, 2978.5 ± 46.574.3 ± 72.35
Triglycerides , Week 48, n=280, 28912.8 ± 68.994.4 ± 70.43
SecondaryChange From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96

Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Millimoles per liter
Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 96
Millimoles per literDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Serum or Plasma Cholesterol, Week 960.379 ± 0.0376-0.104 ± 0.0378
HDL Cholesterol, Direct, Week 960.199 ± 0.01560.090 ± 0.0149
LDL Cholesterol, Week 96,0.147 ± 0.0338-0.154 ± 0.0303
Triglycerides, Week 96,0.129 ± 0.0835-0.112 ± 0.0358
SecondaryChange From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144

Blood samples were collected to perform evaluation of fasting lipids which included Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Millimoles per liter
Change From Baseline in Fasting Lipids-Serum or Plasma Cholesterol, Serum or Plasma HDL Cholesterol (Direct), Serum or Plasma LDL Cholesterol (Calculated or Direct) and Serum or Plasma Triglycerides at Week 144
Millimoles per literDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Serum or Plasma Cholesterol, Week 144,0.367 ± 0.0408-0.037 ± 0.0406
HDL Cholesterol, Direct, Week 1440.181 ± 0.01500.098 ± 0.0147
LDL Cholesterol, Week 144,0.170 ± 0.0336-0.105 ± 0.0348
Triglycerides, Week 1440.117 ± 0.0872-0.104 ± 0.0385
SecondaryPercentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48

Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value is the latest pre-dose assessment (Day 1). Percentage change from Baseline was calculated as 100 multiplied by (\[post-dose visit value minus Baseline value\] divided by Baseline value).

Time frame:
Baseline (Day 1) and at Weeks 24, 48
Reported as:
Mean · Percentage change
Percentage Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Weeks 24, 48
Percentage changeDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Total/HDL Cholesterol Ratio, Week 24, n=294, 297-4.0 ± 19.08-4.6 ± 27.52
Total/HDL Cholesterol Ratio, Week 48, n=280, 289-0.2 ± 31.10-4.4 ± 16.96
SecondaryChange From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96

Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented.

Time frame:
Baseline (Day 1) and at Week 96
Reported as:
Mean · Ratio
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96
RatioDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 96-0.213 ± 0.0566-0.402 ± 0.0479
SecondaryChange From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144

Blood samples were collected to perform evaluation of fasting lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio. Baseline value was defined as the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error has been presented.

Time frame:
Baseline (Day 1) and at Week 144
Reported as:
Mean · Ratio
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144
RatioDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in Fasting Lipid-Serum or Plasma Total Cholesterol/HDL Cholesterol Ratio at Week 144-0.229 ± 0.0559-0.386 ± 0.0463
SecondaryPercentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48

Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Weeks 24 and 48 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 48 or those who had Baseline lipids-lowering agents are not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded to the nearest whole digit.

Time frame:
Weeks 24 and Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Weeks 24, 48
Percentage of participantsDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Week 24, n=309, 31642
Week 48, n=318, 32043
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Fisher Exact · p = 0.157 (Fisher's exact p-value.) · Difference in percentage: 2.0 · 95% CI -0.6 to 4.6Week 24
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Fisher Exact · p = 0.414 (Fisher's exact p-value.) · Difference in percentage: 1.3 · 95% CI -1.7 to 4.2Week 48
SecondaryPercentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96

Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). The higher the grade, the more severe the symptoms. Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 96 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 96 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded to the nearest whole digit.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 96
Percentage of participantsDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 9654
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Fisher Exact · p = 0.562 (Fisher's exact p-value.) · Difference in percentage: 1.0 · 95% CI -2.1 to 4.1Week 96
SecondaryPercentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144

Blood samples were collected to perform evaluation of fasting LDL cholesterol. Any abnormalities were evaluated by the investigator and graded according to DAIDS toxicity scales from Grade 1 to 4 (1=Mild, 2=Moderate, 3=Severe, 4=Potentially life threatening). Percentage of participants with Grade 2 or greater laboratory abnormalities in fasting LDL cholesterol by Week 144 have been presented. Participants without any post-Baseline fasting LDL cholesterol value prior to Week 144 or those who had Baseline lipids-lowering agents were not included. Lipid Last Observation Carried Forward (LOCF) data was used such that the last available fasted, on-treatment lipid value prior to the initiation of a lipid-lowering agent was used in place of future observed values. Percentage values are rounded to the nearest whole digit.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 144
Percentage of participantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Percentage of Participants With Grade 2 or Greater Laboratory Abnormalities in Fasting LDL Cholesterol by Week 14454
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Fisher Exact · p = 0.587 (Fisher's exact p-value.) · Difference in percentage: 0.9 · 95% CI -2.4 to 4.3Week 144
SecondaryPercentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200, \>200), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian, Other). Percentage values are rounded to the nearest whole digit.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count, Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 24
Percentage of participantsDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Baseline CD4+ cell count, <=200,n=31,299086
Baseline CD4+ cell count, >200,n=325,3299394
Female, n=59, 529396
Male, n=297, 3069292
Age, <35,n= 211, 2059395
Age, 35 to <50,n=116, 1079193
Age, >=50, n=29, 469385
Baseline plasma HIV-1 RNA, <=100000,n=282,2829395
Baseline plasma HIV-1 RNA, >100000,n=74, 769287
Race, White, n=244,2479395
Race, African American/African H., n=39, 369281
Race, Asian, n=37, 428993
Race, Other, n=36, 339494
SecondaryPercentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200, \>200), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian, Other). Percentage values are rounded to the nearest whole digit.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 48
Percentage of participantsDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Baseline CD4+ cell count, <=200,n=31,298190
Baseline CD4+ cell count, >200,n=325,3299193
Female, n=59, 528894
Male, n=297, 3069092
Age, <35,n= 211, 2059293
Age, 35 to <50,n=116, 1078694
Age, >=50, n=29, 469087
Baseline plasma HIV-1 RNA, <=100000,n=282,2829093
Baseline plasma HIV-1 RNA, >100000,n=74, 768891
Race, White, n=244,2479094
Race, African American/African H., n=39, 368781
Race, Asian, n=37, 429298
Race, Other, n=36, 338994
SecondaryPercentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded to the nearest whole digit.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 96
Percentage of participantsDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Baseline CD4+ cell count, <=200,n=31, 296590
Baseline CD4+ cell count, >200,n=325,3298689
Female, n=59, 528388
Male, n=297,306,8590
Age, <35,n= 211, 2058490
Age, 35 to <50,n=116, 1078489
Age, >=50, n=29,468687
Baseline plasma HIV-1 RNA, <=100000,n=282,2828590
Baseline plasma HIV-1 RNA, >100000,n=74, 768188
Race, White, n=244,2478690
Race, African American/African H., n=39,367981
Race, Asian, n=37, 427890
Race, Other, n=36, 338691
SecondaryPercentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144

Percentage of participants by subgroups (by age, gender, Baseline CD4+ cell count, Baseline HIV-1 RNA, race) with HIV-1 RNA\<50 c/mL was obtained using FDA Snapshot algorithm. The Snapshot algorithm treated all participants without HIV-1 RNA data at the visit of interest (due to missing data or discontinuation of investigational product prior to the visit window) as non-responders, as well as participants who switch their concomitant ART prior to the visit of interest. Data was presented by subgroups: age (\<35, 35 to \<50, \>=50 years); gender (males and females), Baseline CD4+ cell count (\<=200 cells/mm\^3, \>200 cells/mm\^3), Baseline HIV-1 RNA (\<=100000, \>100000) and Race (White, African American/African H., Asian and other). Percentage values are rounded to the nearest whole digit.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants by Subgroups (by Age, Gender, Baseline CD4+ Cell Count Baseline HIV-1 RNA, Race) With Plasma HIV-1 RNA <50 c/mL at Week 144
Percentage of participantsDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Baseline CD4+ cell count, <=200,n=31, 295883
Baseline CD4+ cell count, >200,n=325,3298183
Female, n=59, 527185
Male, n=297,306,8082
Age, <35,n= 211, 2057783
Age, 35 to <50,n=116, 1078183
Age, >=50, n=29,468378
Baseline plasma HIV-1 RNA, <=100000,n=282,2827982
Baseline plasma HIV-1 RNA, >100000,n=74, 767887
Race, White, n=244,2478285
Race, African American/African H., n=39,366972
Race, Asian, n=37, 427381
Race, Other, n=36, 337879
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 24 by Subgroups

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age, Gender, and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

Time frame:
Baseline (Day 1) and Week 24
Reported as:
Mean · Cells per cubic millimeter
Changes From Baseline in CD4+ Cell Counts at Week 24 by Subgroups
Cells per cubic millimeterDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Baseline plasma HIV-1 RNA,<=100000, n=268,268187.72 ± 10.860167.93 ± 10.842
Baseline plasma HIV-1 RNA,>100000, n=72,73206.63 ± 21.107205.96 ± 20.990
Baseline CD4+ cell count,<=200, n=29,27157.01 ± 33.113120.17 ± 34.151
Baseline CD4+ cell count,>200, n=311, 314195.11 ± 10.026180.73 ± 9.972
Age, <35,n= 203,199202.76 ± 12.456177.62 ± 12.563
Age, 35 to <50, n=109, 100172.05 ± 16.983179.87 ± 17.733
Age, >=50, n=28, 42188.79 ± 33.534159.34 ± 27.344
Female, n=57,50199.45 ± 23.498181.78 ± 25.263
Male, n=283,291190.21 ± 10.538175.05 ± 10.400
Race, White, n=236,235204.78 ± 11.531182.27 ± 11.582
Race, African Am/African H., n=36,33143.84 ± 29.541170.51 ± 30.870
Race, Asian, n=34, 41169.80 ± 30.491165.36 ± 27.782
Race, Other, n=34,32174.30 ± 30.375149.34 ± 31.404
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 19.80 · 95% CI -10.23 to 49.83Baseline plasma HIV-1 RNA,\<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and HIV-1 RNA interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 0.67 · 95% CI -57.07 to 58.40Baseline plasma HIV-1 RNA,\>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and HIV-1 RNA interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 36.84 · 95% CI -55.94 to 129.63Baseline CD4+ cell count,\<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 14.37 · 95% CI -13.38 to 42.12Baseline CD4+ cell count,\>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 25.14 · 95% CI -9.56 to 59.85Age\<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): -7.82 · 95% CI -55.98 to 40.34Age 35 to \<50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 29.45 · 95% CI -55.47 to 114.38Age\>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 17.67 · 95% CI -49.89 to 85.23Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 15.16 · 95% CI -13.90 to 44.21Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 22.51 · 95% CI -9.52 to 54.54Race group white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race group, and treatment and race group interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): -26.67 · 95% CI -110.64 to 57.30Race group African Am/African H.. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race group, and treatment and race group interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 4.44 · 95% CI -76.18 to 85.06Race group Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race group, and treatment and race group interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 24.96 · 95% CI -60.68 to 110.59Race group Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race group, and treatment and race group interaction.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 48 by Subgroups

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the latest pre-dose assessment (Day 1). Change from Baseline was defined as post-dose visit value minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from Analysis of Covariance (ANCOVA) model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · Cells per cubic millimeter
Changes From Baseline in CD4+ Cell Counts at Week 48 by Subgroups
Cells per cubic millimeterDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Baseline plasma HIV-1 RNA,<=100000, n=257,264220.0 ± 11.72212.4 ± 11.56
Baseline plasma HIV-1 RNA,>100000, n=67,70238.5 ± 23.09235.5 ± 22.70
Baseline CD4+ cell count,<=200, n=26, 27200.5 ± 36.97177.9 ± 36.18
Baseline CD4+ cell count,>200, n=298, 307225.9 ± 10.84220.7 ± 10.68
Age group-1, <35,n= 194, 192233.6 ± 13.49225.2 ± 13.53
Age group-1, 35 to <50, n=104, 101208.7 ± 18.40211.2 ± 18.67
Age group-1, >=50, n=26, 41212.6 ± 36.84194.8 ± 29.27
Female, n=54, 49237.1 ± 25.53226.8 ± 26.98
Male, n=270, 285221.2 ± 11.41215.6 ± 11.11
Race, White, n=224, 231226.0 ± 12.55219.7 ± 12.39
Race, African Am/African H., n=33, 31209.4 ± 32.75239.9 ± 33.79
Race, Asian, n=34, 41246.4 ± 32.35197.2 ± 29.47
Race, Other, n=33, 31200.2 ± 32.69202.7 ± 33.83
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 7.6 · 95% CI -24.6 to 39.8Baseline plasma HIV-1 RNA,\<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count and treatment and HIV-1 RNA interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 3.0 · 95% CI -59.8 to 65.9Baseline plasma HIV-1 RNA,\>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count and treatment and HIV-1 RNA interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 22.6 · 95% CI -78.3 to 123.5Baseline CD4+ cell count,\<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 5.2 · 95% CI -24.7 to 35.1Baseline CD4+ cell count,\>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 8.4 · 95% CI -29.1 to 45.9Age\<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): -2.5 · 95% CI -53.9 to 48.9Age 35 to \<50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 17.7 · 95% CI -74.6 to 110.1Age\>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 10.4 · 95% CI -62.3 to 83.1Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 5.6 · 95% CI -25.6 to 36.9Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 6.3 · 95% CI -28.2 to 40.9Race group white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race group, and treatment and race group interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): -30.2 · 95% CI -122.7 to 62.4Race group African Am/African H.. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race group, and treatment and race group interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 49.2 · 95% CI -36.3 to 134.7Race group Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race group, and treatment and race group interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): -2.5 · 95% CI -94.7 to 89.7Race group Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race group, and treatment and race group interaction.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 96 by Subgroups

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · Cells per cubic millimeter
Changes From Baseline in CD4+ Cell Counts at Week 96 by Subgroups
Cells per cubic millimeterDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Baseline plasma HIV-1 RNA,<=100000, n=240,253254.8 ± 13.30252.9 ± 12.93
Baseline plasma HIV-1 RNA,>100000, n=61,67300.2 ± 26.50260.1 ± 25.42
Baseline CD4+ cell count,<=200, n=21,26240.5 ± 45.16244.4 ± 40.44
Baseline CD4+ cell count,>200, n=280,294265.9 ± 12.28255.1 ± 11.98
Age group-1, <35,n= 179,185270.2 ± 15.38263.0 ± 15.09
Age group-1, 35 to <50, n=97,95259.5 ± 20.86262.0 ± 21.09
Age group-1, >=50, n=25, 40237.6 ± 41.11195.9 ± 32.45
Female, n=49,46277.9 ± 29.40259.1 ± 30.54
Male, n=252, 274261.4 ± 12.95253.5 ± 12.43
Race group, White, n=210,223275.2 ± 14.21260.0 ± 13.80
Race group, African Am/African H., n=31,29228.5 ± 37.07230.2 ± 38.23
Race group, Asian, n=29,38212.1 ± 38.34244.8 ± 33.53
Race group, Other, n=31,30273.4 ± 36.97247.3 ± 37.67
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 1.9 · 95% CI -34.5 to 38.2Baseline plasma HIV-1 RNA,\<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 40.1 · 95% CI -31.2 to 111.5Baseline plasma HIV-1 RNA,\>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and HIV-1 RNA interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): -3.9 · 95% CI -122.3 to 114.5Baseline CD4+ cell count,\<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 10.8 · 95% CI -22.9 to 44.5Baseline CD4+ cell count,\>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 7.3 · 95% CI -35.0 to 49.6Age Group,\<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): -2.5 · 95% CI -60.7 to 55.7Age Group,35 to \<50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 41.6 · 95% CI -61.2 to 144.5Age\>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 18.8 · 95% CI -64.2 to 101.8Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 7.8 · 95% CI -27.4 to 43.1Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 15.2 · 95% CI -23.6 to 54.0Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): -1.7 · 95% CI -106.3 to 103.0Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Median difference (net): -32.6 · 95% CI -132.2 to 66.9Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · Mean difference (net): 26.1 · 95% CI -77.3 to 129.5Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
SecondaryChanges From Baseline in CD4+ Cell Counts at Week 144 by Subgroups

CD4+ cells are type of white blood cells that fight infection and as HIV infection progresses, the number of these cells declines. Blood samples were collected at specified time points to assess CD4+. It was evaluated by flow cytometry. Baseline value is the the latest pre-dose assessment (Day 1). Change from Baseline was defined as value at the indicated time point minus Baseline value. Adjusted mean and standard error is presented for subgroups (Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, Age group, Gender and race). For each subgroup, adjusted mean is the estimated mean change from Baseline in each arm calculated from ANCOVA model adjusting for the following covariates/factors: treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, subgroup, and treatment and relevant subgroup interaction. For CD4+ cell count subgroup, Baseline CD4+ cell count group is included as a factor only.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Mean · Cells per cubic millimeter
Changes From Baseline in CD4+ Cell Counts at Week 144 by Subgroups
Cells per cubic millimeterDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Baseline plasma HIV-1 RNA,<=100000, n=214,223295.7 ± 14.14296.1 ± 13.84
Baseline plasma HIV-1 RNA,>100000, n=56, 64334.3 ± 27.77329.6 ± 26.15
Baseline CD4+ cell count,<=200, n=17, 24290.2 ± 50.44272.9 ± 42.29
Baseline CD4+ cell count,>200, n=253, 263304.7 ± 12.97306.2 ± 12.71
Age group, <35,n=155, 167298.0 ± 16.59316.0 ± 15.93
Age group-1, 35 to <50, n=92, 87305.6 ± 21.48302.1 ± 22.11
Age group-1, >=50, n=23,33337.4 ± 43.01242.2 ± 35.83
Female, n=43, 43346.6 ± 31.40321.7 ± 31.67
Male, n=227, 244295.9 ± 13.66300.0 ± 13.20
Race group, White, n=190,201314.2 ± 14.93314.0 ± 14.53
Race group, African Am/African H., n=26, 26243.8 ± 40.42295.1 ± 40.39
Race group, Asian, n=26, 34244.0 ± 40.47264.1 ± 35.41
Race group, Other, n=28,26346.2 ± 38.87279.9 ± 40.42
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): -0.4 · 95% CI -39.2 to 38.3Baseline plasma HIV-1 RNA,\<=100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and relevant Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 4.7 · 95% CI -69.4 to 78.8Baseline plasma HIV-1 RNA,\>100000. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, Baseline plasma HIV-1 RNA, and treatment and Baseline plasma HIV-1 RNA interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 17.4 · 95% CI -111.1 to 145.8Baseline CD4+ cell count,\<=200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): -1.5 · 95% CI -37.2 to 34.1Baseline CD4+ cell count,\>200. Following covariates were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, and treatment and Baseline CD4+ cell count interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): -18.0 · 95% CI -63.2 to 27.1Age Group,\<35. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 3.5 · 95% CI -57.0 to 64.0Age Group,35 to \<50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 95.2 · 95% CI -14.8 to 205.2Age Group,\>=50. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, age, and treatment and age interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 24.9 · 95% CI -62.5 to 112.3Female. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): -4.2 · 95% CI -41.5 to 33.1Male. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, gender, and treatment and gender interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 0.3 · 95% CI -40.6 to 41.1Race group-white. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): -51.3 · 95% CI -163.6 to 60.9Race group-African Am/African H. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Median difference (net): -20.1 · 95% CI -125.3 to 85.0Race group-Asian. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · Mean difference (net): 66.2 · 95% CI -43.7 to 176.2Race group-Other. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count, race, and treatment and race interaction.
SecondaryChange From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment (Day 1) and change from Baseline=post-dose value minus Baseline value.

Time frame:
Baseline (Day 1) and Weeks 4, 24, 48
Reported as:
Mean · Scores on a scale
Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Utility Score at Weeks 4, 24, 48
Scores on a scaleDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Week 4, n=349, 3480.0130 ± 0.003620.0078 ± 0.00353
Week 24, n=352, 3510.0131 ± 0.003710.0168 ± 0.00333
Week 48, n=352, 3510.0134 ± 0.003840.0129 ± 0.00349
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · MMRM · p = 0.302 · Mean difference (net): 0.0052 · 95% CI -0.0047 to 0.0152Week 4. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit with visit as the repeated factor
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · MMRM · p = 0.450 · Mean difference (net): -0.0038 · 95% CI -0.0136 to 0.0060Week24. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit with visit as the repeated factor
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · MMRM · p = 0.934 · Mean difference (net): 0.0004 · 95% CI -0.0098 to 0.0106Week48. Following covariates/factors were adjusted: Treatment, Baseline plasma HIV-1 RNA (factor), Baseline CD4+ cell count (factor), and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit with visit as the repeated factor
SecondaryChange From Baseline in EQ-5D-5L Utility Score at Week 96

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment (Day 1) and change from Baseline=post-dose value minus Baseline value.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L Utility Score at Week 96
Scores on a scaleDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Change From Baseline in EQ-5D-5L Utility Score at Week 960.0079 ± 0.004500.0091 ± 0.00408
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · MMRM · p = 0.842 · Mean difference (net): -0.0012 · 95% CI -0.0132 to 0.0107Week 96. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
SecondaryChange From Baseline in EQ-5D-5L Utility Score at Week 144

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has 1 question assessing each of 5 dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. The health state is defined by combining the levels of answers from each of the 5 questions. Each health state is referred to in terms of a 5 digit code. Health state 5 digit code is translated into utility score, which is valued up to 1 (perfect health) with lower values meaning worse state. EQ-5D-5L utility score ranges from -0.281 to 1. Higher scores indicate better health. Baseline was the latest pre-dose assessment (Day 1) and change from Baseline=post-dose value minus Baseline value.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L Utility Score at Week 144
Scores on a scaleDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in EQ-5D-5L Utility Score at Week 1440.0143 ± 0.003880.0135 ± 0.00365
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = 0.879 · Mean difference (net): 0.0008 · 95% CI -0.0097 to 0.0113Week 144. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count, and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
SecondaryChange From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24 48

EQ-5D-5L questionnaire provides a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value.

Time frame:
Baseline (Day 1) and Weeks 4, 24, 48
Reported as:
Mean · Scores on a scale
Change From Baseline in EuroQol - 5 Dimensions - 5 Levels (EQ-5D-5L) Thermometer Scores at Weeks 4, 24 48
Scores on a scaleDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Week 4, n=349, 3482.3 ± 0.481.2 ± 0.52
Week 24, n=352, 3503.7 ± 0.543.2 ± 0.51
Week 48, n=352, 3504.3 ± 0.492.8 ± 0.49
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · MMRM · p = 0.137 · Mean difference (net): 1.1 · 95% CI -0.3 to 2.4Week 4. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA (factor),Baseline CD4+ cell count (factor), Baseline EQ-5D thermometer, treatment\*visit and Baseline EQ-5D thermometer\*visit with visit as the repeated factor
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · MMRM · p = 0.458 · Mean difference (net): 0.6 · 95% CI -0.9 to 2.0Week24. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA (factor),Baseline CD4+ cell count (factor), Baseline EQ-5D thermometer, treatment\*visit and Baseline EQ-5D thermometer\*visit with visit as the repeated factor
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · MMRM · p = 0.031 · Mean difference (net): 1.5 · 95% CI 0.1 to 2.8Week48. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA (factor),Baseline CD4+ cell count (factor), Baseline EQ-5D thermometer, treatment\*visit and Baseline EQ-5D thermometer\*visit with visit as the repeated factor
SecondaryChange From Baseline in EQ-5D-5L Thermometer Scores at Week 96

EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 96
Scores on a scaleDTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind Phase
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 964.1 ± 0.512.4 ± 0.56
Statistical analysis
  • DTG + 3TC-Double Blind Phase vs DTG + TDF/FTC-Double Blind Phase · MMRM · p = 0.027 · Mean difference (net): 1.7 · 95% CI 0.2 to 3.2Week 96. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.
SecondaryChange From Baseline in EQ-5D-5L Thermometer Scores at Week 144

EQ-5D-5L questionnaire provided a profile of participant function and a global health state rating. The five-item measure has one question assessing each of five dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression and 5 levels for each dimension including 1=no problems, 2=slight problems, 3=moderate problems, 4=severe problems and 5=extreme problems. EQ-5D-5L included EQ visual Analogue scale (EQ VAS) 'Thermometer' which provided Self-rated current health status. Score ranges from 0 (worst imaginable health state) to 100 (best imaginable health state). MMRM was run on the LOCF dataset, using the observed margins (OM) option. Baseline was the latest pre-dose assessment value (Day 1) and change from Baseline=post-dose value minus Baseline value. Adjusted mean and standard error is presented.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Mean · Scores on a scale
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 144
Scores on a scaleDTG + 3TC - Double-blind Phase + Open-label PhaseDTG + TDF/FTC - Double-blind Phase + Open-label Phase
Change From Baseline in EQ-5D-5L Thermometer Scores at Week 1445.2 ± 0.483.0 ± 0.50
Statistical analysis
  • DTG + 3TC - Double-blind Phase + Open-label Phase vs DTG + TDF/FTC - Double-blind Phase + Open-label Phase · MMRM · p = 0.001 · Mean difference (net): 2.3 · 95% CI 0.9 to 3.6Week 144. Covariates adjusted: Treatment, Baseline plasma HIV-1 RNA, Baseline CD4+ cell count and Baseline EQ-5D utility, treatment\*visit and Baseline EQ-5D utility\*visit as factors and covariate, with visit as the repeated factor.

Adverse events

Collected over All-cause mortality, SAEs and non-SAEs were collected up to Week 148 in Double-blind Phase + Open-label Phase and from Week 148 to Week 280 in Continuation Phase. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
DTG + 3TC-Double-blind Phase + Open-label Phase1/356 (0.3%)37/356 (10.4%)272/356 (76.4%)
DTG + TDF/FTC-Double-blind Phase + Open-label Phase0/358 (0%)38/358 (10.6%)268/358 (74.9%)
DTG + 3TC-Continuation Phase0/233 (0%)5/233 (2.1%)46/233 (19.7%)
Most frequent serious events
Showing 10 of 60
Most frequent serious events
EventDTG + 3TC-Double-blind Phase + Open-label PhaseDTG + TDF/FTC-Double-blind Phase + Open-label PhaseDTG + 3TC-Continuation Phase
Hepatitis AInfections and infestations3/3564/3581/233
AppendicitisInfections and infestations1/3564/3582/233
Suicide attemptPsychiatric disorders3/3560/3580/233
NephrolithiasisRenal and urinary disorders0/3563/3580/233
PneumoniaInfections and infestations2/3561/3580/233
Abscess limbInfections and infestations2/3560/3580/233
Anogenital wartsNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3560/3580/233
Hodgkin's diseaseNeoplasms benign, malignant and unspecified (incl cysts and polyps)2/3560/3580/233
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/3562/3580/233
CellulitisInfections and infestations1/3562/3580/233
Most frequent other events
Showing 10 of 62
Most frequent other events
EventDTG + 3TC-Double-blind Phase + Open-label PhaseDTG + TDF/FTC-Double-blind Phase + Open-label PhaseDTG + 3TC-Continuation Phase
NasopharyngitisInfections and infestations49/35658/3587/233
DiarrhoeaGastrointestinal disorders50/35653/3580/233
HeadacheNervous system disorders51/35647/3587/233
SyphilisInfections and infestations38/35640/3586/233
PharyngitisInfections and infestations38/35630/3586/233
Upper respiratory tract infectionInfections and infestations37/35633/3587/233
InsomniaPsychiatric disorders29/35636/3580/233
NauseaGastrointestinal disorders13/35632/3580/233
BronchitisInfections and infestations30/35621/3580/233
Vitamin D deficiencyMetabolism and nutrition disorders25/35622/3580/233

Baseline characteristics

Baseline Characteristic data are reported for the Intent-to-Treat Exposed (ITT-E) Population which consisted of all randomized participants who received at least one dose of study treatment.

Age, Continuous
Age, Continuous(Years)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind PhaseTotal
Mean34.0 ± 9.8835.0 ± 10.7234.5 ± 10.31
Sex: Female, Male
Sex: Female, Male(Participants)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind PhaseTotal
Female5952111
Male297306603
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)DTG + 3TC-Double Blind PhaseDTG + TDF/FTC-Double Blind PhaseTotal
Race — American (Am) Indian or Alaska (Al.) native312859
Race — Asian-Central/South Asian heritage (H.)044
Race — Asian - East Asian H.333669
Race — Asian - South East Asian H.426
Race — Black or African Am393675
Race — Native Hawaiian or other Pacific Islander202
Race — White (Wt)-Arabic/North African H.5510
Race — White - White/Caucasian/European H.239242481
Race — Multiple358
09

Study locations

90 sites
  • GSK Investigational Site
    Phoenix, Arizona 85015, United States
  • GSK Investigational Site
    Washington, District of Columbia 20037, United States
  • GSK Investigational Site
    Fort Pierce, Florida 34982, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33407, United States
  • GSK Investigational Site
    Decatur, Georgia 30033, United States
  • GSK Investigational Site
    Indianapolis, Indiana 46202, United States
  • GSK Investigational Site
    Springfield, Massachusetts 01199, United States
  • GSK Investigational Site
    Berkley, Michigan 48072, United States
  • GSK Investigational Site
    Kansas City, Missouri 64111, United States
  • GSK Investigational Site
    Saint Louis, Missouri 63108, United States
  • GSK Investigational Site
    Chapel Hill, North Carolina 27599-7064, United States
  • GSK Investigational Site
    Allentown, Pennsylvania 18102, United States
  • GSK Investigational Site
    Providence, Rhode Island 02906, United States
  • GSK Investigational Site
    Bellaire, Texas 77401, United States
  • GSK Investigational Site
    Ciudad Autonoma de Buenos Aires, Buenos Aires C1181ACH, Argentina
  • GSK Investigational Site
    Ciudad Autónoma de Buenos Aires, Buenos Aires C1405CKC, Argentina
  • GSK Investigational Site
    Buenos Aires, 1141, Argentina
  • GSK Investigational Site
    Buenos Aires, 1202, Argentina
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Sydney, New South Wales 2010, Australia
  • GSK Investigational Site
    Fortitude Valley, Queensland 4006, Australia
  • GSK Investigational Site
    Antwerpen, 2000, Belgium
  • GSK Investigational Site
    Brussels, 1000, Belgium
  • GSK Investigational Site
    Brussels, 1070, Belgium
  • GSK Investigational Site
    Bruxelles, 1200, Belgium
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4E9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2L 4P9, Canada
  • GSK Investigational Site
    Le Kremlin-Bicetre Cedex, 94275, France
  • GSK Investigational Site
    Marseille, 13003, France
  • GSK Investigational Site
    Paris Cedex 10, 75475, France
  • GSK Investigational Site
    Paris Cedex 12, 75571, France
  • GSK Investigational Site
    Paris, 75013, France
  • GSK Investigational Site
    Toulouse Cedex 9, 31059, France
  • GSK Investigational Site
    Muenchen, Bayern 80336, Germany
  • GSK Investigational Site
    Bonn, Nordrhein-Westfalen 53127, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45122, Germany
  • GSK Investigational Site
    Berlin, 10439, Germany
  • GSK Investigational Site
    Hamburg, 20146, Germany
  • GSK Investigational Site
    Bologna, Emilia-Romagna 40138, Italy
  • GSK Investigational Site
    Ferrara, Emilia-Romagna 44100, Italy
  • GSK Investigational Site
    Genova, Liguria 16132, Italy
  • GSK Investigational Site
    Brescia, Lombardia 25123, Italy
  • GSK Investigational Site
    Busto Arsizio (VA), Lombardia 21052, Italy
  • GSK Investigational Site
    Milano, Lombardia 20127, Italy
  • GSK Investigational Site
    Pavia, Lombardia 27100, Italy
  • GSK Investigational Site
    Padova, 35128, Italy
  • GSK Investigational Site
    Reggio Emilia, 42121, Italy
  • GSK Investigational Site
    Roma, 00149, Italy
  • GSK Investigational Site
    Busan, 49241, Korea, Republic of
  • GSK Investigational Site
    Daegu, 41944, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Seoul, 152-703, Korea, Republic of
  • GSK Investigational Site
    Guadalajara, Jalisco 44160, Mexico
  • GSK Investigational Site
    Zapopan, Jalisco 45170, Mexico
  • GSK Investigational Site
    Distrito Federal, 06470, Mexico
  • GSK Investigational Site
    Rotterdam, 3015 CE, Netherlands
  • GSK Investigational Site
    Rotterdam, 3079 DZ, Netherlands
  • GSK Investigational Site
    Coimbra, 3000-075, Portugal
  • GSK Investigational Site
    Lisboa, 1169-050, Portugal
  • GSK Investigational Site
    Porto, 4369-004, Portugal
  • GSK Investigational Site
    Cluj-Napoca, 400348, Romania
  • GSK Investigational Site
    Galati, 800179, Romania
  • GSK Investigational Site
    Ekaterinburg, 620149, Russian Federation
  • GSK Investigational Site
    Krasnojarsk, 660049, Russian Federation
  • GSK Investigational Site
    Moscow, 105275, Russian Federation
  • GSK Investigational Site
    Orel, 302040, Russian Federation
  • GSK Investigational Site
    St. Petersburg, 196645, Russian Federation
  • GSK Investigational Site
    Toliyatti, 445846, Russian Federation
  • GSK Investigational Site
    Observatory, Cape Town, 7925, South Africa
  • GSK Investigational Site
    Alicante, 03010, Spain
  • GSK Investigational Site
    Badalona, 08916, Spain
  • GSK Investigational Site
    Córdoba, 14004, Spain
  • GSK Investigational Site
    Elche (Alicante), 03203, Spain
  • GSK Investigational Site
    Madrid, 28007, Spain
  • GSK Investigational Site
    Madrid, 28031, Spain
  • GSK Investigational Site
    Madrid, 28034, Spain
  • GSK Investigational Site
    Madrid, 28911, Spain
  • GSK Investigational Site
    Mataró, 08304, Spain
  • GSK Investigational Site
    San Sebastian, 20080, Spain
  • GSK Investigational Site
    Santiago de Compostela, 15706, Spain
  • GSK Investigational Site
    Valencia, 46014, Spain
  • GSK Investigational Site
    Vigo, 36312, Spain
  • GSK Investigational Site
    Kaohsiung, 824, Taiwan
  • GSK Investigational Site
    Taipei, 100, Taiwan
  • GSK Investigational Site
    Taipei, 11217, Taiwan
  • GSK Investigational Site
    London, SE1 9RT, United Kingdom
  • GSK Investigational Site
    London, SW10 9NH, United Kingdom
  • GSK Investigational Site
    Manchester, M8 5RB, United Kingdom
10

References and documents

Publications

  • Cahn P, Madero JS, Arribas JR, Antinori A, Ortiz R, Clarke AE, Hung CC, Rockstroh JK, Girard PM, Sievers J, Man C, Currie A, Underwood M, Tenorio AR, Pappa K, Wynne B, Fettiplace A, Gartland M, Aboud M, Smith K; GEMINI Study Team. Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with HIV-1 infection (GEMINI-1 and GEMINI-2): week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials. Lancet. 2019 Jan 12;393(10167):143-155. doi: 10.1016/S0140-6736(18)32462-0. Epub 2018 Nov 9. Erratum In: Lancet. 2019 Jan 12;393(10167):132. doi: 10.1016/S0140-6736(18)33041-1. PubMed 30420123 ↗
  • Ait-Khaled M, Sierra Madero J, Estrada V, Gulminetti R, Hagins D, Tsai HC, Man C, Sievers J, Grove R, Zolopa A, Wynne B, van Wyk J. Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies. HIV Res Clin Pract. 2021 Dec 9;23(1):9-14. Epub 2021 Dec 16. PubMed 34913844 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2016 to primary completion in Mar 2018, 20 months.

Results were first posted in Apr 2019, 1 year after primary completion.

Of 57 industry-sponsored phase 3 interventional studies under HIV Infections, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 30. This study's 20 months is close to that.

Counting every sponsor, half of 101 studies reached it within 27 months; a quarter within 20 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2016
First posted
Jul 13, 2016
StartActual
Jul 21, 2016
Primary completionActual
Mar 29, 2018
CompletionActual
Aug 15, 2022
Results first posted
Apr 18, 2019
Last update
Aug 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02831673
Lead sponsor
ViiV Healthcare
Collaborators
PPD DEVELOPMENT, LP, GlaxoSmithKline
Responsible party
Sponsor
First posted
Jul 13, 2016
Start date
Jul 21, 2016
Primary completion
Mar 29, 2018
Completion
Aug 15, 2022
Results posted
Apr 18, 2019
Last update
Aug 24, 2023

Study contacts

GSK Clinical Trials
study director · ViiV Healthcare

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lamivudine

Start the discussion